University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
James C. Lee, MD

James C. Lee, MD

Clinical Instructor, Division of Hematology & Oncology, UCSF

Research Summary

I have a research focus in adoptive T cell therapy using chimeric antigen receptors (CARs) and checkpoint inhibitors. My current interest is on the design of next generation of CARs and combination checkpoint immunotherapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.

Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity. Using the liver as a model organ of immune tolerance, I intend to study the mechanism of tumor escape in the setting of checkpoint inhibition and adoptive T cell therapy.

My hope is to see cancer immunotherapeutics become its own mainstream anatomic-site agnostic cancer subspecialty.

Professional Experience:

Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013

Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014

Education:

Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009

Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.

Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012

Selected Publications

  1. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology. 2020; PMID: 33008914.
    View on PubMed
  2. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 08; 67(8):1471-1480.
    View on PubMed
  3. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14).
    View on PubMed
  4. Holohan DR, Lee JC, Bluestone JA. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-402.
    View on PubMed
  5. Lee JC*, Pegram HJ*, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 18(119):4133-41.
    View on PubMed
  6. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011 Apr 15; 71(8):2871-81.
    View on PubMed
  7. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 2009 Mar; 15(3):338-44.
    View on PubMed
  8. Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol. 2009; 506:83-96.
    View on PubMed
  9. Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009.
    View on PubMed

Go to UCSF Profiles, powered by CTSI